financetom
Business
financetom
/
Business
/
Boyd Gaming Insider Sold Shares Worth $1,271,800, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Boyd Gaming Insider Sold Shares Worth $1,271,800, According to a Recent SEC Filing
Mar 5, 2024 3:03 PM

05:52 PM EST, 03/05/2024 (MT Newswires) -- Stephen S. Thompson, Chief Administrative Officer, on March 04, 2024, sold 20,000 shares in Boyd Gaming ( BYD ) for $1,271,800. Following the Form 4 filing with the SEC, Thompson has control over a total of 85,746 shares of the company, with 38,621 shares held directly and 47,125 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/906553/000106299324005568/xslF345X03/form4.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Portillo's Insider Sold Shares Worth $679,675, According to a Recent SEC Filing
Portillo's Insider Sold Shares Worth $679,675, According to a Recent SEC Filing
Aug 12, 2024
03:56 PM EDT, 08/12/2024 (MT Newswires) -- Michael Osanloo, Director, President & CEO, on August 09, 2024, sold 66,052 shares in Portillo's (PTLO) for $679,675. Following the Form 4 filing with the SEC, Osanloo has control over a total of 79,041 shares of the company, with 79,041 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1871509/000187150924000105/xslF345X03/wk-form4_1723492418.xml Price: 10.82, Change: +0.11, Percent Change: +1.03...
Novartis loses initial bid to block generic of best-selling heart drug
Novartis loses initial bid to block generic of best-selling heart drug
Aug 12, 2024
Aug 12 (Reuters) - Novartis failed to convince a Delaware federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to a court decision issued on Monday. U.S. District Judge Richard Andrews ruled that Novartis' chance of winning its patent-infringement lawsuit challenging the generic was too low to justify halting...
Update: Eli Lilly Looking to Issue Debt for Morphic Acquisition
Update: Eli Lilly Looking to Issue Debt for Morphic Acquisition
Aug 12, 2024
03:45 PM EDT, 08/12/2024 (MT Newswires) -- (Updates to reflect Eli Lilly ( LLY ) declined comment to MT Newswires) Eli Lilly ( LLY ) filed a prospectus Monday to raise debt for its $3.2 billion acquisition of Morphic. According to a securities filing, the pharma company is looking to issue five separate series of notes to raise $5 billion...
Esperion Therapeutics Shares Fall After Reporting Wider Than Expected Q2 Loss
Esperion Therapeutics Shares Fall After Reporting Wider Than Expected Q2 Loss
Aug 12, 2024
03:45 PM EDT, 08/12/2024 (MT Newswires) -- Esperion Therapeutics ( ESPR ) shares were down nearly 8% in recent Monday trading after the company reported a wider-than-expected Q2 net loss. The company reported a Q2 net loss of $0.33 per diluted share, compared with a loss of $0.46 a year earlier. Analysts polled by Capital IQ expected a $0.18 loss....
Copyright 2023-2026 - www.financetom.com All Rights Reserved